Vanguard Group’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $51.4K | Buy |
777
+297
| +62% | +$55.3K | ﹤0.01% | 4243 |
|
|
2025
Q3 | $127K | Buy |
480
+418
| +674% | +$113K | ﹤0.01% | 4193 |
|
|
2025
Q2 | $9.34K | Hold |
62
| – | – | ﹤0.01% | 4264 |
|
|
2025
Q1 | $30.1K | Hold |
62
| – | – | ﹤0.01% | 4227 |
|
|
2024
Q4 | $52.6K | Sell |
62
-81
| -57% | -$98.1K | ﹤0.01% | 4211 |
|
|
2024
Q3 | $203K | Sell |
143
-26
| -15% | -$37.5K | ﹤0.01% | 4142 |
|
|
2024
Q2 | $297K | Buy |
169
+18
| +12% | +$41.6K | ﹤0.01% | 4101 |
|
|
2024
Q1 | $445K | Buy |
151
+7
| +5% | +$29.8K | ﹤0.01% | 4046 |
|
|
2023
Q4 | $927K | Hold |
144
| – | – | ﹤0.01% | 3851 |
|
|
2023
Q3 | $462K | Hold |
144
| – | – | ﹤0.01% | 4072 |
|
|
2023
Q2 | $625K | Hold |
144
| – | – | ﹤0.01% | 4056 |
|
|
2023
Q1 | $1.04M | Hold |
144
| – | – | ﹤0.01% | 3905 |
|
|
2022
Q4 | $1.14M | Hold |
144
| – | – | ﹤0.01% | 3861 |
|
|
2022
Q3 | $1.14M | Hold |
144
| – | – | ﹤0.01% | 3961 |
|
|
2022
Q2 | $1.56M | Hold |
144
| – | – | ﹤0.01% | 3920 |
|
|
2022
Q1 | $1.92M | Sell |
144
-1
| -0.7% | -$11.5K | ﹤0.01% | 3975 |
|
|
2021
Q4 | $2.02M | Buy |
145
+5
| +4% | +$88.7K | ﹤0.01% | 4036 |
|
|
2021
Q3 | $3.16M | Hold |
140
| – | – | ﹤0.01% | 3892 |
|
|
2021
Q2 | $3.84M | Buy |
140
+78
| +126% | +$2.13M | ﹤0.01% | 3726 |
|
|
2021
Q1 | $1.91M | Buy |
62
+49
| +377% | +$1.8M | ﹤0.01% | 3870 |
|
|
2020
Q4 | $472K | Sell |
13
-1
| -7% | -$35.5K | ﹤0.01% | 3961 |
|
|
2020
Q3 | $509K | Sell |
14
-20
| -59% | -$850K | ﹤0.01% | 3813 |
|
|
2020
Q2 | $1.5M | Sell |
34
-25
| -42% | -$1.19M | ﹤0.01% | 3517 |
|
|
2020
Q1 | $1.62M | Buy |
59
+1
| +2% | +$34.1K | ﹤0.01% | 3356 |
|
|
2019
Q4 | $2.38M | Hold |
58
| – | – | ﹤0.01% | 3400 |
|
|
2019
Q3 | $2.89M | Sell |
58
-2
| -3% | -$103K | ﹤0.01% | 3321 |
|
|
2019
Q2 | $3.35M | Buy |
60
+42
| +233% | +$2.28M | ﹤0.01% | 3307 |
|
|
2019
Q1 | $647K | Buy |
18
+3
| +20% | +$179K | ﹤0.01% | 3727 |
|
|
2018
Q4 | $716K | Hold |
15
| – | – | ﹤0.01% | 3656 |
|
|
2018
Q3 | $1.07M | Hold |
15
| – | – | ﹤0.01% | 3702 |
|
|
2018
Q2 | $1.18M | Buy |
15
+3
| +25% | +$246K | ﹤0.01% | 3645 |
|
|
2018
Q1 | $984K | Buy |
12
+2
| +20% | +$173K | ﹤0.01% | 3651 |
|
|
2017
Q4 | $855K | Buy |
10
+1
| +11% | +$86.5K | ﹤0.01% | 3643 |
|
|
2017
Q3 | $1.02M | Buy |
9
+2
| +29% | +$211K | ﹤0.01% | 3587 |
|
|
2017
Q2 | $631K | Buy |
7
+1
| +17% | +$43.5K | ﹤0.01% | 3683 |
|
|
2017
Q1 | $309K | Buy |
+6
| New | +$420K | ﹤0.01% | 3834 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 4044 |
|
Other funds holding MBRX
Vanguard Group's MBRX Position: Q4 2025 in Review
Vanguard Group increased its Moleculin Biotech (MBRX) stake by 62% in Q4 2025, buying an estimated $55.3K and bringing the position to 777 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4243.
Vanguard Group first reported a position in MBRX in Q1 2017 and has held it in 36 quarters since. The position peaked at $3.84M in Q2 2021. 14 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.
- Vanguard Group held 777 shares of Moleculin Biotech worth $51.4K as of Q4 2025.
- Vanguard Group bought 297 Moleculin Biotech shares in Q4 2025, an estimated $55.3K.
- Moleculin Biotech made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4243 holding.
- Vanguard Group first reported a position in Moleculin Biotech in Q1 2017 and has held it in 36 quarters since.
- Vanguard Group's Moleculin Biotech position peaked at $3.84M in Q2 2021.
- 14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.